Translational Lung Cancer Research is newly included by Scopus
News

Translational Lung Cancer Research is newly included by Scopus

Chao-Xiu (Melanie) He

Editorial Office, Translational Lung Cancer Research, AME Publishing Company, Guangzhou 510000, China

Correspondence to: Chao-Xiu (Melanie) He, Science Editor. Editorial Office, Translational Lung Cancer Research, AME Publishing Company, Room 11, 14/F, Chuangzhan Habor Building, No. 82, Jiangnan Main Road, Haizhu District, Guangzhou 510000, China. Email: editor@tlcr.org.

Submitted Oct 31, 2015. Accepted for publication Nov 05, 2015.

doi: 10.3978/j.issn.2218-6751.2015.11.01


It is great to share with all the readers that Translational Lung Cancer Research (TLCR) has been accepted for inclusion in Scopus since October 2015. Scopus is one of the largest databases of peer-reviewed literature: scientific journals, books and conference proceedings in the world. This is another international recognition for TLCR after being indexed by PubMed.

Since first launched in March 2012, TLCR’s each step of development has been witnessed by its increasing number of readers worldwide. It is published quarterly in 2012, and bimonthly since February 2013. TLCR has been highlighted by MDLinx since December 2012, covered by Medscape since September 2013, and indexed by the Chemical Abstracts Service (CAS) Databases from May 2014, by PubMed/PubMed Central since December 2014, and by Scopus in October 2015 (Figure 1). Meanwhile, TLCR is accessible to a much wider range of readers via these different portals. More importantly, with more and more recognition from the international scientific community, the impact of TLCR is increasing as well (Table 1).

Figure 1 The timeline of TLCR’s development. TLCR, Translational Lung Cancer Research.
Table 1
Table 1 Part of TLCR’s articles cited by peer influential journals (IF >3.00)
Full table

Though TLCR develops at a fast speed, there is no shortcut. TLCR persists to collaborate with the world-class experts throughout the world (Figures 2,3), with flexible novel formats to publish high-quality articles focusing on cutting-edge developments at the transition from preclinical to clinical research and thus closes the gap between “bench and bedside”, to meet multiple needs of global readers, and to pioneer the field of translational research of lung cancer.

Figure 2 The geographical distribution of Editorial Board Members of Translational Lung Cancer Research (TLCR) (updated in April, 2015).
Figure 3 The geographical distribution of all authors of Translational Lung Cancer Research (TLCR) (updated in April, 2015).

Especially after being indexed by PubMed in December 2014, TLCR enters a new developing stage with a faster growing speed as compared with the development as before (1). Its publications not only come out regularly, but also focus on the up-to-date topics which are heatedly debated and well-received by readers, such as the three focused issues published in 2015.

  • Vol 4, No.2 (April, 2015), Focused Issue on Molecular Genetics of Lung Cancer, Guest Editor: Dr. Wendy A. Cooper, Royal Prince Alfred Hospital;
  • Vol 4, No.4 (August, 2015), Focused Issue on Improving the Quality and Outcomes of Lung Cancer Care: An Interdisciplinary Approach, Guest Editor: Dr. Raymond U. Osarogiagbon, Baptist Cancer Center;
  • Vol 4, No.5 (October, 2015), Focused Issue on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care, Guest Editor: Dr. Edward S. Kim, from Levine Cancer Institute.

Actually, the three focused issues along with former ones published in 2013 and 2014 have come out as previously planned, which shows that TLCR is apt to publish focused issues as scheduled with its collaborative efforts with Guest Editors, authors and the editorial team. And TLCR will continue to bring more high-quality focused issues to meet its global readers’ demands (Table 2).

Table 2
Table 2 Future focused issues to be published on Translational Lung Cancer Research (TLCR)
Full table

Along with the development of science and technology, more controversies emerge, and debates need evidences to support and resolve. Therefore, new special sections “Controversies on Lung Cancer” (Figure 4) and “Evidence-Based Medicine” (Figure 5) have been established in TLCR after sufficient preparations.

Figure 4 Articles in TLCR’s new special section “Controversies on Lung Cancer: Pros and Cons”. TLCR, Translational Lung Cancer Research.
Figure 5 Articles in TLCR’s new special section “Evidence-Based Medicine”. TLCR, Translational Lung Cancer Research.

Moreover, we are happy to see that TLCR is growing together with its Editorial Board Members and authors. In May of this year, the study “EML4-ALK rearrangement in blood platelets and outcometo crizotinib in non-small-cell lung cancer patients” of our Co-Editor-in-Chief Dr. Rafael Rosell and his team were presented at the annual congress of the American Society of Clinical Oncology (ASCO) in Chicago (Figure 6). On the 16th World Conference on Lung Cancer (WCLC) held in Denver in September, Honorary Editor-in-Chief, Editorial Board Member and Author of TLCR, have respectively won three out of the four International Association for the Study of Lung Cancer (IASLC) distinguished awards (Figure 7). The IASLC Paul A. Bunn, JR. Scientific Award was given to Professor Yi-Long Wu from China, the Honorary Editor-in-Chief of TLCR; the Mary J. Matthews Pathology/Translational Research Award given to Professor Ming Sound Tsao from Canada, the Editorial Board Member of TLCR; and the Joseph W. Cullen Prevention/Early Detection Award given to Professor Jacek Jassem, Author of TLCR and Editorial Board Member of our sister journal Annals of Translational Medicine (ATM).

Figure 6 The study “EML4-ALK rearrangement in blood platelets and outcometo crizotinib in non-small-cell lung cancer patients” of our Co-Editor-in-Chief Dr. Rafael Rosell and his team were presented at the annual congress of the American Society of Clinical Oncology (ASCO) in Chicago.
Figure 7 Honorary Editor-in-Chief, Editorial Board Member and Author of TLCR, have respectively won three out of the four IASLC distinguished awards. TLCR, Translational Lung Cancer Research; IASLC, International Association for the Study of Lung Cancer.

Growing together with its editorial board members and authors, TLCR is encouraged by these experts who know it well, especially the prominent experts in the field of translational lung cancer research (Figures 8-11).

Figure 8 Encouraging words from Professor Rafael Rosell.
Figure 9 Encouraging words from Professor James L. Mulshine.
Figure 10 Encouraging words from Professor John D. Minna.
Figure 11 Encouraging words from Professor Robert Pirker.

In less than 2 months, about 30 distinguished experts in the field of lung cancer have given their testimonial words to TLCR. This is encouraging. We are honored to have their great contributions and encouragements on the road of TLCR’s growth. This is indispensable for the progresses that TLCR has made.

Embracing with all the encouragements and collaborative efforts with Editorial Board, Guest Editors, Authors, Reviewers and Readers worldwide, TLCR will continue to step forward and make contribution to the field of translational lung cancer research!


Acknowledgements

None.


Footnote

Conflicts of Interest: The author has no conflicts of interest to declare.


References

  1. He MC, Li GS. Translational Lung Cancer Research is indexed by PubMed. Transl Lung Cancer Res 2015;4:1-4. [PubMed]
Cite this article as: He CX. Translational Lung Cancer Research is newly included by Scopus. Transl Lung Cancer Res 2015;4(6):828-835. doi: 10.3978/j.issn.2218-6751.2015.11.01

Refbacks

  • There are currently no refbacks.